Related Experiment Video
Updated: Feb 16, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Patients lacking glycemic control place more burdens on health services with the use of medications
Ana Márcia Tomé Camargos1, Ana Carolina Oliveira Gonçalves1, Maurílio de Souza Cazarim2
1Federal University of São João Del-Rei (UFSJ), Rua Sebastião Gonçalves Coelho, 400, Bairro Chanadour, Divinópolis, MG, CEP: 35.501-296, Brazil.
Introduction:
DM spending in the world is high, and Brazilian studies of public spending caused by DM are scarce.
Objective:
To estimate the annual direct cost for the municipal health sphere, related to DM2 treatment, in patients with and without glycemic control.
Method:
A cross-sectional study carried out in a city in the interior of Minas Gerais state, with patients with DM2, being municipal PHS users. Data were collected from the computerized system of the municipality and patient records, and analyzed using the IBM SPSS v.19 statistical package. The response variable was categorized into controlled A1c (≤7%) and uncontrolled A1c (>7%).
Results:
Glycemic control in 56.6% of the patients was unsatisfactory; the mean cost of pharmacotherapy for DM2 was US$ 3.14 per year for patients in the control group and US$ 45.54 per year for uncontrolled patients.
Conclusion:
Patients with unsatisfactory glycemic control are more expensive for the municipal health system.
More Related Videos
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Hypoglycemia and Glucagon
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...

